Nidan Laboratories & Healthcare Ltd
Incorporated in 2000, Nidan Laboratories & Healthcare Ltd is in the business of providing various Healthcare and Diagnostics Services[1]
- Market Cap ₹ 20.8 Cr.
- Current Price ₹ 15.0
- High / Low ₹ 24.9 / 12.8
- Stock P/E 9.00
- Book Value ₹ 50.1
- Dividend Yield 0.00 %
- ROCE 6.17 %
- ROE 2.92 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.30 times its book value
- Debtor days have improved from 39.1 to 18.9 days.
Cons
- The company has delivered a poor sales growth of 2.76% over past five years.
- Company has a low return on equity of 2.60% over last 3 years.
- Earnings include an other income of Rs.2.39 Cr.
- Promoter holding has decreased over last 3 years: -14.2%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Part of Nifty SME Emerge
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 20.07 | 21.41 | 20.38 | 29.66 | 24.27 | 24.18 | 24.53 | 27.11 | |
| 12.23 | 13.78 | 11.49 | 20.25 | 17.47 | 17.74 | 19.47 | 22.11 | |
| Operating Profit | 7.84 | 7.63 | 8.89 | 9.41 | 6.80 | 6.44 | 5.06 | 5.00 |
| OPM % | 39.06% | 35.64% | 43.62% | 31.73% | 28.02% | 26.63% | 20.63% | 18.44% |
| 0.37 | 0.01 | 1.06 | 0.40 | 3.33 | -3.76 | 2.25 | 2.39 | |
| Interest | 4.75 | 3.74 | 3.46 | 2.66 | 2.22 | 2.18 | 2.14 | 2.14 |
| Depreciation | 3.24 | 3.19 | 3.18 | 2.63 | 3.10 | 2.87 | 2.41 | 1.99 |
| Profit before tax | 0.22 | 0.71 | 3.31 | 4.52 | 4.81 | -2.37 | 2.76 | 3.26 |
| Tax % | 0.00% | 0.00% | 30.21% | 41.15% | 26.40% | 36.29% | 28.26% | |
| 0.22 | 0.71 | 2.30 | 2.66 | 3.54 | -3.23 | 1.98 | 2.31 | |
| EPS in Rs | 0.22 | 0.72 | 2.32 | 1.91 | 2.55 | -2.32 | 1.42 | 1.66 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 3% |
| 3 Years: | -6% |
| TTM: | 18% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 23% |
| 3 Years: | -7% |
| TTM: | 20% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -30% |
| 1 Year: | -27% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 4% |
| 3 Years: | 3% |
| Last Year: | 3% |
Balance Sheet
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9.90 | 9.90 | 9.90 | 13.90 | 13.90 | 13.90 | 13.90 | 13.90 |
| Reserves | 0.41 | 1.13 | 3.43 | 52.00 | 55.54 | 52.31 | 54.28 | 55.72 |
| 32.16 | 34.35 | 38.04 | 19.29 | 10.93 | 12.44 | 11.11 | 12.50 | |
| 0.58 | -0.17 | 2.37 | 3.29 | 4.03 | 3.90 | 3.65 | 3.64 | |
| Total Liabilities | 43.05 | 45.21 | 53.74 | 88.48 | 84.40 | 82.55 | 82.94 | 85.76 |
| 23.28 | 20.10 | 19.92 | 20.46 | 21.39 | 17.95 | 16.33 | 15.50 | |
| CWIP | 0.00 | 0.00 | 0.23 | 3.81 | 0.00 | 0.04 | 0.15 | 0.15 |
| Investments | 0.53 | 0.53 | 0.27 | 0.00 | 0.00 | 0.00 | 20.00 | 20.00 |
| 19.24 | 24.58 | 33.32 | 64.21 | 63.01 | 64.56 | 46.46 | 50.11 | |
| Total Assets | 43.05 | 45.21 | 53.74 | 88.48 | 84.40 | 82.55 | 82.94 | 85.76 |
Cash Flows
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 8.95 | 4.62 | 4.35 | 7.83 | 10.97 | 5.52 | 2.28 | |
| 1.00 | -0.01 | -3.22 | -35.74 | -0.29 | -10.60 | -0.22 | |
| -5.81 | -1.56 | -1.22 | 28.72 | -10.37 | -0.49 | -3.01 | |
| Net Cash Flow | 4.14 | 3.05 | -0.10 | 0.80 | 0.32 | -5.57 | -0.95 |
| Free Cash Flow | 9.95 | 4.61 | 1.13 | 1.36 | 11.02 | 4.88 | 1.41 |
| CFO/OP | 114% | 61% | 49% | 96% | 162% | 129% | 77% |
Ratios
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 102.03 | 92.57 | 97.25 | 65.96 | 90.69 | 7.85 | 18.90 |
| Inventory Days | 16.98 | 12.88 | 18.17 | 25.99 | |||
| Days Payable | 116.72 | -25.76 | 213.05 | 135.84 | |||
| Cash Conversion Cycle | 2.29 | 131.22 | -97.64 | -43.89 | 90.69 | 7.85 | 18.90 |
| Working Capital Days | 256.25 | 291.69 | -189.31 | 54.52 | 43.46 | 243.18 | -13.39 |
| ROCE % | 10.13% | 13.99% | 10.09% | 8.17% | 7.95% | 6.17% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Trade Receivable Turnover Ratio Ratio |
|
||||
| Number of Permanent Employees Number |
|||||
| Revenue from Pathology Rs. in Lakhs |
|||||
| Revenue from Radiology Rs. in Lakhs |
|||||
| Number of Diagnostic Centers Number |
|||||
Extracted by Screener AI
Documents
Announcements
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
8 April 2026 - Submitted Regulation 74(5) demat certificate for quarter ended 31 March 2026.
-
Updates
3 April 2026 - Nidan Laboratories says Regulation 24A annual secretarial compliance report is not applicable.
-
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
2 April 2026 - Corporate governance provisions not applicable for quarter ended 31 March 2026 under SME exemption.
-
Trading Window
23 March 2026 - Trading window closed from 1 April 2026 until 48 hours after audited results for year ended 31 March 2026.
-
Shareholders meeting
7 March 2026 - Postal ballot (6 Feb–7 Mar 2026): five related-party resolutions approved; ~99.45% favor, 1.32% turnout.
Business Overview:[1]
NLHL is a Healthcare Division of Nidan Group. It operates 35 diagnostic centers across Greater Mumbai under the Nidan Diagnostics brand. Services include CT scan, MRI, Ultrasound, 2D Echo, ECG, and more.